Trimeris Reformulates Strategy*

            


Details


Case Code : CLBS093
Publication date : 2009
Subject : Business Strategy
Industry : -
Length : 02 Pages
Price : Rs. 100

To download this case click on the button below, and select the case from the list of available cases:

» Business Strategy
Short Case Studies

» Business Strategy Case Studies**
» Case Studies Collection
» ICMR Courseware
» View Detailed Pricing Info

Key words:

Strategy, Trimeris, downsizing, research and development, fusion inhibitor technology, Fuzeon, TRI-1144, HealthCor, patent infringement, Novartis, drug delivery system, Pfizer, Merck, Roche

Note

* This caselet is intended for use only in class discussions.
** More comprehensive case studies are priced at Rs.200 to Rs.700 (US $5 to US $16) per copy.

 


Abstract:
ICMR India ICMR India ICMR India ICMR India RSS Feed

With sales of its only commercially available product failing to pick up significantly and the company being encircled by a number of problems, Trimeris announced its plans to downsize the company by scaling back its investments in research and development (R&D) and laying off workers.

Introduction

On December 11, 2007, Trimeris Inc. (Trimeris) announced its plans to downsize the company by scaling back its investments in research and development (R&D) and laying off its R&D workers in 2008. Announcing the new strategy, Martin Mattingly (Mattingly), CEO, Trimeris, said, "The company plans to evaluate a full range of options for maximizing shareholder value, including strategic transactions."

Established by scientists Dani Bolognesi and Tom Mathews in 1993, Trimeris was a US-based biopharmaceutical company specializing in fusion inhibitor technology. The company was in the business of developing and commercializing drugs for the treatment of viral diseases.


Mattingly's announcement came close on the heels of Trimeris' announcement that it planned to launch a new version of its breakthrough drug Fuzeon, called TR-1144, in 2008...

Cases on Related Topics

1. Pricing Fuzeon: Cost of Innovation

2. Race-Specific Drug 'BiDil': Nitromed's Marketing Challenge

3. HSBC's Restructuring in India

4. Employee Downsizing - A Global Phenomenon

Google